AMResolute is developing a novel class of compounds, called AQNOs.
AQNOs poison the electron transport chain, thereby leading to the eradication of the microbe. The AQNOs and AQNO derived compounds currently in development are against three different bacterial pathogens: Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus, all of which are on the WHO’s list of “bacteria for which new antibiotics are urgently needed”. For example, our data provide strong impetus to explore AQNOs as a novel treatment option for multidrug-resistant gonococci.
Our AQNOs not only show remarkable potency even against multidrug-resistant gonococci strains but also stand out by their high selectivity against only pathogenic gonococci. By this pathogenic gonococci are effectively eradicated while the natural microbial flora stays intact.
Thereby, the new active agent could not only be suitable for effective treatment, but also be used as a prophylaxis for particularly vulnerable population groups.